📢 TEC Inaugural Members Summit | November 5–6, 2026 | ZEISS Innovation Center, Dublin, California | Attendance by Invitation Only

📢 TEC Inaugural Members Summit | November 5–6, 2026 | ZEISS Innovation Center, Dublin, California | Attendance by Invitation Only

Explore the Summit
Join TEC
Meet with TEC
Email TEC

Meet Our Consortium Partners

About Visible Genomics

Visible Genomics

AMDiGuard™

AMD Genetic Risk Testing

AMD Progression Testing

Genetic Insights

Personalized AMD Care

Patient Education

Brand Highlights

Want to Identify AMD Risk Earlier?

Visible Genomics helps eye care professionals bring more personalized insight to AMD care with AMDiGuard™, a comprehensive genetic-based AMD risk and progression test that combines genetic and non-genetic factors into a single integrated risk score.

  • Comprehensive risk insight — Better understand individual patient risk to support informed monitoring, counseling, and preventive care conversations.
  • Simple in-office collection — A quick cheek swab requires no blood draw.
  • Timely results — Receive results in approximately 3–4 weeks.
  • Patient education resources — Educational materials support patient conversations, while risk-factor checklists capture non-genetic inputs for the integrated score.
  • Practice-ready support — Staff training, onboarding assistance, and ongoing support make implementation easier.

 

Exclusive TEC Member Pricing. TEC members receive exclusive pricing on AMDiGuard™. Visit Visible Genomics Provider Page and mention TEC in your inquiry to receive member pricing.

Image gallery marquee
Image gallery marquee

Bringing Genetic Insight to Personalized AMD Care

Visible Genomics is focused on making genetic-based AMD risk assessment more accessible and practical for optometry and ophthalmology practices.

Through AMDiGuard™, the company helps eye care professionals incorporate comprehensive genetic-based AMD risk and progression testing into patient counseling and individualized care planning.

Beyond testing, Visible Genomics provides educational resources, staff training, and implementation support to help practices confidently introduce genetic risk assessment into patient care.

What’s Included with AMDiGuard™?

  • Comprehensive genetic-based AMD risk and progression testing
  • Integrated risk score incorporating genetic and non-genetic factors
  • Buccal swab sample collection kit
  • Patient risk-factor checklist to capture non-genetic inputs for the integrated risk score
  • Patient education materials
  • Clinical and front-office staff training resources
  • Practice onboarding and ongoing customer support

Preferred Access for TEC Members

TEC members receive exclusive pricing on AMDiGuard™ and access to resources that help practices evaluate and implement genetic-based AMD risk testing.

Member Benefits

  • Preferred pricing — Exclusive TEC member pricing is available for AMDiGuard™. Contact Visible Genomics for pricing details.
  • HSA/FSA-eligible testing — AMDiGuard™ testing offers patients an additional payment option through eligible health savings and flexible spending accounts.
  • Complimentary training materials — Resources for clinical and front-office teams.
  • Priority onboarding support — Assistance as your practice introduces AMDiGuard™.
  • Dedicated customer support — Ongoing help with the testing process.
  • No commitment to get started — Explore the solution and available resources before deciding whether to implement testing.

 

Interested in AMDiGuard™?

Visit complete the physician inquiry form, and mention TEC to request member pricing, sample-kit information, and training resources.

Clinically Relevant. Practice-Ready. Patient-Focused.

Visible Genomics brings together comprehensive genetic-based AMD risk and progression assessment and practical resources for everyday eye care.

  • Clinically grounded — An integrated risk score combines genetic and non-genetic factors to inform individualized risk discussions.
  • Practice-ready — Collection and implementation are designed for optometry and ophthalmology settings.
  • Patient-focused — Educational resources help explain risk information and support shared conversations about monitoring and lifestyle.

AMDiGuard™ Genetic-Based AMD Risk and Progression Testing

AMDiGuard™ is one comprehensive genetic-based AMD test that provides either AMD risk assessment or AMD progression assessment, depending on the clinical need. It combines a comprehensive genetic panel with non-genetic risk factors in an integrated score and is intended to complement clinical examination and professional judgment.

Risk and Progression Insight

Clinicians can select the AMD risk or progression assessment appropriate to the patient, using the results alongside clinical findings to inform monitoring and counseling.

Patient and Practice Resources

Sample collection materials, patient education, and staff resources support use of the testing service within an established care process.

A Partnership Supporting More Informed AMD Care

Visible Genomics and The Eye Consortium (TEC) aim to make genetic-based AMD risk assessment more accessible to independent eye care practices through member pricing, education, and implementation support.

What the Partnership Brings

  • Access — Exclusive TEC member pricing for AMDiGuard™.
  • Clinical perspective — Additional risk information to consider alongside examination findings and patient history.
  • Implementation support — Resources for introducing testing into existing workflows.
  • Patient communication — Educational tools to support informed discussions about AMD risk.

Designed for Independent Eye Care

The collaboration is focused on practical resources that help independent practices evaluate whether genetic-based AMD risk assessment is appropriate for their patients and workflows.

Simple Testing. Seamless Integration.

AMDiGuard™ is designed to fit into routine eye care visits with a straightforward process:

  1. Introduce Testing — Discuss AMD genetic testing with the patient and provide educational information.
  2. Collect the Sample — Complete the clinical information and consent forms, then collect a simple cheek swab.
  3. Submit for Analysis — Send the sample to the lab for genetic analysis and integrated risk assessment.
  4. Review Results — Receive results in approximately 3–4 weeks to support personalized patient counseling and care planning.
Join TEC Today ||

Have Questions? Let’s Connect